NCT03392246 2026-01-22
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT03944772 2025-01-30
ORCHARD
AstraZeneca
Phase 2 Active not recruiting
NCT01306045 2024-10-01
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02337530 2024-03-21
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00890825 2018-06-20
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
AstraZeneca
Phase 2 Completed
NCT03004105 2018-03-16
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01229150 2017-05-23
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00372788 2014-08-13
AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
AstraZeneca
Phase 2 Completed